Introduction
============

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. The prevalence of the disease is projected to increase as the population ages and as exposure to risk factors, such as smoking, continues.[@b1-copd-12-2487]--[@b3-copd-12-2487] COPD is characterized by breathlessness, episodes of exacerbations, and reduced exercise capacity.[@b4-copd-12-2487] Decreased exercise capacity can result in reduced ability to perform the activities of daily living, and the resultant inactivity and sedentary lifestyle can further exacerbate exercise-capacity impairment.[@b5-copd-12-2487],[@b6-copd-12-2487]

In clinical practice, spirometry is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for the diagnosis of COPD.[@b4-copd-12-2487] However, spirometry is a poor predictor of disability and health-related quality of life (HRQoL) in patients with COPD,[@b7-copd-12-2487] and correlates weakly with dyspnea, exercise capacity, and health status.[@b8-copd-12-2487]--[@b10-copd-12-2487] Functional evaluations, such as exercise tests, are thus recommended in addition to spirometry. However, there is currently no single standard test for the assessment of exercise capacity. Field-based tests routinely used to measure exercise capacity include the 6-minute walk test (6MWT),[@b11-copd-12-2487] 12MWT,[@b12-copd-12-2487] incremental shuttle walk test (ISWT),[@b13-copd-12-2487] and endurance SWT (ESWT).[@b14-copd-12-2487] Laboratory-based assessments allow the researcher to monitor several concomitant physiological variables, such as heart rate, workload performed, and oxygen consumption. Such tests include the incremental cycle ergometer test (ICET), endurance CET (ECET), and treadmill test (TT). It has been demonstrated that COPD and its consequent limitation of daily activity affect the HRQoL of patients.[@b15-copd-12-2487] Exercise tests are designed to reflect a patient's exercise capacity, but how accurately they reflect patients' HRQoL as assessed by patient-reported outcomes (PROs) of HRQoL and breathlessness in individuals with COPD is unclear. While there have been studies in which exercise tests have been included in the validation of new PRO instruments,[@b16-copd-12-2487],[@b17-copd-12-2487] it has elsewhere been reported that improvements in exercise capacity elicited by rehabilitation do not necessarily correlate with HRQoL PROs in patients with COPD.[@b18-copd-12-2487]

Several questions remain regarding the associations between exercise tests and PROs. Which PROs are independent of exercise and which are not? Which, if any, PROs accurately and consistently reflect the ability of a patient with COPD to perform exercise? The purpose of this systematic review was to assess the strength of the available evidence supporting correlations between the outcomes of different exercise tests and the PROs most commonly used to assess HRQoL and breathlessness.

Materials and methods
=====================

Search strategy
---------------

Literature searches were conducted using Ovid, incorporating MedLine (1948 to January 22, 2013, then updated to include articles from July 23, 2012 to September 13, 2016), Embase (1974 to January 22, 2013 and July 23, 2012 to September 13, 2016), and the Cochrane Library (to January 22, 2013 and July 23, 2012 to September 12, 2016). Search strings were constructed to identify study publications (including those specific to emphysema and bronchitis) reporting primary data on the outcomes of the following exercise tests in patients with COPD: 6MWT, 12MWT, ISWT, ESWT, ICET, ECET, and TT. The full search strings used have been published previously.[@b19-copd-12-2487]

Study selection
---------------

Study selection followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for performing a systematic literature review.[@b20-copd-12-2487] Publications were initially screened based on titles and abstracts, and full articles were reviewed when their relevance was unclear from the abstract. Publications were excluded if they were review articles, not in English, studied patients with confounding comorbidities (eg, cancers or diabetes), unclear on the precise variables used for regression analysis, or examined an inappropriate intervention (eg, nonbronchodilatory pharmacotherapy or homeopathy). Articles were subsequently included for assessment only if they reported data on the correlations (Pearson's *r* and/or Spearman's *ρ*) between any of the prespecified exercise tests and PRO measures, such as the St George's Respiratory Questionnaire (SGRQ)[@b17-copd-12-2487] total and individual domain scores (while the former is the usual means of reporting SGRQ data, significant correlations may exist within individual domains alone), the 36-item Short-Form Health Survey (SF-36),[@b21-copd-12-2487] the five-domain European QoL questionnaire (EQ-5D),[@b22-copd-12-2487],[@b23-copd-12-2487] the Chronic Respiratory Disease Questionnaire (CRQ),[@b24-copd-12-2487] the baseline dyspnea index (BDI),[@b25-copd-12-2487] the oxygen-cost diagram (OCD),[@b26-copd-12-2487] the Medical Research Council dyspnea scale (MRC),[@b27-copd-12-2487] and the modified MRC dyspnea scale (mMRC).[@b28-copd-12-2487] MRC and mMRC correlations were reported in combination, given that they report the same scale on different intervals.

Exercise tests and PRO measures
-------------------------------

### Exercise tests and respiratory-related PRO measures

The SGRQ is a disease-specific, self-administered questionnaire assessing symptoms, activity, and impacts on health status in COPD and asthma. Lower scores are associated with improved health status.[@b29-copd-12-2487] The CRQ is a comprehensive HRQoL questionnaire specific for individuals with COPD that assesses dyspnea, fatigue, emotional function, and mastery (the feeling of control over the disease and its effects). Each component is scored using a 7-point Likert scale, which can be combined to produce a total score of 20--140, with higher scores indicating improvement.[@b24-copd-12-2487] The BDI questionnaire assesses the severity of dyspnea based on the three components of functional impairment, magnitude of task, and magnitude of effort, which are rated from 0 (very severe) to 4 (no impairment). These scores can be combined to produce a focal score of 0--12, with higher scores indicating improved health status.[@b25-copd-12-2487] The OCD assesses dyspnea and measures the oxygen requirement of different activity levels. It is scored from 0 to 100 mm, with higher scores indicating greater improvement.[@b26-copd-12-2487] The MRC is a simple questionnaire that evaluates the effect of breathlessness on daily activities by grading patients' perceptions of breathlessness from 1 to 5, with lower grades indicating less breathlessness and improved health status.[@b30-copd-12-2487] The mMRC is a 5-point version of this questionnaire.[@b31-copd-12-2487]

### Exercise tests and non-disease-specific PRO measures

The SF-36 is a generic questionnaire of 36 items, which assesses physical functioning, social functioning, role limitations (physical), role limitations (emotional), emotional well-being, mental health, energy and vitality, pain, general health perceptions, and current general health perceptions compared with the previous year to determine the general health status of a patient. Higher scores indicate better health status.[@b32-copd-12-2487] The EQ-5D is another measure that assesses HRQoL across the five dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored from 1 (no problem) to 3 (severe problem). The test also includes a visual analog scale to measure general HRQoL from 0 to 100, with 100 representing the best health condition.[@b22-copd-12-2487]

Inclusion/exclusion criteria and data abstraction
-------------------------------------------------

Owing to a lack of high-quality evidence for associations between these tests and the prespecified PRO measures, we included observational studies in our final analysis in addition to randomized controlled trials. In our literature search, we reviewed articles to identify those presenting Pearson's and/or Spearman's correlations between our stated PRO measures and the most commonly reported exercise test outcomes. Studies reporting lung-function variables only as a percentage of age-, sex-, and body-mass index-predicted values were excluded. Publications involving studies assessing multivariate regressions were also excluded, owing to the multifactorial nature of the statistical approach and the unsuitability of the output for aggregation.

Data were primarily abstracted by a single reviewer. A randomly generated selection of 30% of all articles was reviewed by a second reviewer in both phases for quality-control purposes. The following outcomes of exercise tests were recorded: distance or stages achieved for the 6MWT, 12MWT, and ISWT, duration of exercise for the ESWT and ECET, and the highest recorded volume of oxygen consumption (peak VO~2~) and maximum workload (W~max~) for the TT and ICET.

Statistical analysis
--------------------

Pearson's and Spearman's correlations between PRO scores and the most commonly reported exercise test outcomes are presented. Pearson's correlations are often used to describe the linear association between two variables when comparing continuous variable data. Spearman's correlations are commonly used to describe the linear association between two sets of ranked (ordinal) data. Correlations are presented as the range of significant values reported in the study publications reviewed. The strength of correlations has been classified according to *British Medical Journal* guidelines, which regard significant correlation coefficients of 0--0.19 as very weak, 0.2--0.39 as weak, 0.4--0.59 as moderate, 0.6--0.79 as strong, and 0.8--1 as very strong.[@b33-copd-12-2487]

Results
=======

Overview of identified studies
------------------------------

The PRISMA-compliant search methodology used to identify relevant articles is summarized in [Figure 1](#f1-copd-12-2487){ref-type="fig"}. Of 3,205 articles screened, 28 were ultimately deemed eligible for inclusion in this review.[@b34-copd-12-2487]--[@b61-copd-12-2487] [Table 1](#t1-copd-12-2487){ref-type="table"} provides a summary of the studies included.

Correlations between exercise test outcomes and patient-reported quality of life-measure outcomes
-------------------------------------------------------------------------------------------------

### St George's Respiratory Questionnaire total score

In total, 13 study publications reported correlations between the SGRQ total score (SGRQ~total~) and one or more exercise test outcomes ([Table 2](#t2-copd-12-2487){ref-type="table"}, [Figure 2](#f2-copd-12-2487){ref-type="fig"}).[@b37-copd-12-2487],[@b41-copd-12-2487]--[@b43-copd-12-2487],[@b45-copd-12-2487],[@b46-copd-12-2487],[@b49-copd-12-2487],[@b50-copd-12-2487],[@b52-copd-12-2487],[@b53-copd-12-2487],[@b55-copd-12-2487],[@b59-copd-12-2487],[@b60-copd-12-2487] Of these, correlations between outcomes from the SGRQ~total~ and distance covered in the 6MWT were most commonly reported. These correlations were typically significant, with six articles reporting weak negative Pearson's correlations of −0.26,[@b37-copd-12-2487] −0.26 (*P*\<0.01),[@b59-copd-12-2487] −0.37 (*P*\<0.05),[@b41-copd-12-2487] −0.37 (*P*=0.0228),[@b49-copd-12-2487] −0.39 (*P*\<0.01),[@b53-copd-12-2487] and −0.39 (*P*=0.01),[@b60-copd-12-2487] demonstrating that as distance covered in the 6MWT increases, SGRQ~total~ scores decrease, indicating better health status. There were also two studies reporting Spearman's correlations of −0.27[@b42-copd-12-2487] (JP de Torres confirmed this was incorrectly reported as 0.27 in the article) and −0.56.[@b50-copd-12-2487] Three papers noted nonsignificant associations between the 6MWT and SGRQ~total~.[@b46-copd-12-2487],[@b52-copd-12-2487],[@b55-copd-12-2487] Limited data were available for other exercise tests, with moderate correlations given for the ISWT (*r*=−0.55[@b45-copd-12-2487], *ρ*=−0.55[@b43-copd-12-2487]), weak--moderate correlations for the ICET (*r*=−0.29 to −0.23,[@b37-copd-12-2487],[@b41-copd-12-2487] *ρ*=−0.49 to −0.36,[@b50-copd-12-2487] depending on the outcome measure obtained \[VO~2~ or W~max~\]), and moderate Spearman's correlations (*ρ*=−0.54[@b50-copd-12-2487] and −0.58[@b43-copd-12-2487]) for the ECET and TT, respectively.

### St George's Respiratory Questionnaire activity domain

Correlations between exercise test outcomes and the SGRQ activity domain score (SGRQ~activity~) were reported in nine study publications ([Table 2](#t2-copd-12-2487){ref-type="table"}).[@b37-copd-12-2487],[@b43-copd-12-2487],[@b45-copd-12-2487],[@b46-copd-12-2487],[@b50-copd-12-2487],[@b53-copd-12-2487],[@b55-copd-12-2487],[@b59-copd-12-2487],[@b60-copd-12-2487] Of these, four articles noted significant weak--strong negative correlations between 6MWT distance and SGRQ~activity~ (*r*=−0.35,[@b37-copd-12-2487] −0.36[@b53-copd-12-2487] \[weak\], and −0.44[@b60-copd-12-2487] \[moderate\]; *ρ*=−0.68[@b50-copd-12-2487] and an unspecified correlation of −0.37[@b46-copd-12-2487]). Two further studies found strong correlations between SGRQ~activity~ and ISWT outcome (*r*=−0.67[@b45-copd-12-2487] and *ρ*=−0.62[@b43-copd-12-2487]), with two more finding no significant association for this relationship.[@b55-copd-12-2487],[@b59-copd-12-2487] One study[@b50-copd-12-2487] reported moderate correlations between SGRQ~activity~ and ICET peak VO~2~ (*ρ*=−0.51) and strong correlations between SGRQ~activity~ and ICET W~max~ (*ρ*=−0.62) and ECET (*ρ*=−0.62), with a weak correlation for the ICET W~max~ found in one other study (*r*=−0.31).[@b37-copd-12-2487] Finally, one publication reported moderate correlations between TT peak VO~2~ and SGRQ~activity~ (*ρ*=−0.58).[@b43-copd-12-2487] Again, these negative correlations suggest that as exercise performance increases, SGRQ~activity~ scores decrease, indicating improved health status.

### St George's Respiratory Questionnaire impact domain

Correlations between exercise test outcomes and the SGRQ impact domain score (SGRQ~impact~) were reported in nine articles ([Table 2](#t2-copd-12-2487){ref-type="table"}).[@b37-copd-12-2487],[@b43-copd-12-2487],[@b45-copd-12-2487],[@b46-copd-12-2487],[@b50-copd-12-2487],[@b53-copd-12-2487],[@b55-copd-12-2487],[@b59-copd-12-2487],[@b60-copd-12-2487] Five studies found weak--moderate correlations between the SGRQ~impact~ and the 6MWT (*r*=−0.22, −0.28, −0.37,[@b37-copd-12-2487],[@b53-copd-12-2487],[@b59-copd-12-2487] and 0.4;[@b60-copd-12-2487] *ρ*=−0.5[@b55-copd-12-2487]), two found moderate evidence for an association between the SGRQ~impact~ and the ISWT (*r*=−0.53[@b45-copd-12-2487] and *ρ*=−0.48[@b43-copd-12-2487]), and there was moderate evidence for an association between the SGRQ~impact~ and the ECET (*ρ*=−0.50)[@b50-copd-12-2487] or TT (*ρ*=−0.54).[@b43-copd-12-2487] A further study found a weak correlation between the SGRQ~impact~ and the ICET W~max~ (*r*=−0.20).[@b37-copd-12-2487]

### St George's Respiratory Questionnaire symptom domain

Very limited data were found concerning associations between the SGRQ symptom domain score (SGRQ~symptom~) and exercise test outcomes ([Table 2](#t2-copd-12-2487){ref-type="table"}). Five studies[@b46-copd-12-2487],[@b50-copd-12-2487],[@b53-copd-12-2487],[@b55-copd-12-2487],[@b60-copd-12-2487] of seven[@b37-copd-12-2487],[@b46-copd-12-2487],[@b50-copd-12-2487],[@b53-copd-12-2487],[@b55-copd-12-2487],[@b59-copd-12-2487],[@b60-copd-12-2487] assessing the association between SGRQ~symptom~ and 6MWT distance reported nonsignificant relationships. In the two studies that reported significant correlations between SGRQ~symptom~ and 6MWT, very weak negative (−0.03)[@b37-copd-12-2487] and weak negative (−0.35)[@b59-copd-12-2487] correlations were found. Two studies[@b45-copd-12-2487],[@b55-copd-12-2487] of three[@b43-copd-12-2487],[@b45-copd-12-2487],[@b55-copd-12-2487] examining ISWT found no correlation with SGRQ~symptom~. One article reported weak (*ρ*=−0.34) and moderate (*ρ*=−0.44) correlations between the SGRQ~symptom~ and the ISWT and TT, respectively.[@b43-copd-12-2487]

### St George's Respiratory Questionnaire for COPD

One study publication reported on the relationship between the 6MWT and the disease-specific SGRQ for COPD (SGRQ-c); however, this study examined risk factors, and reported only that worse (higher) SGRQ-c scores were an independent predictor of lower 6MWT distances.[@b62-copd-12-2487]

### Other quality-of-life instruments

Too few publications reporting associations between exercise test outcomes and the SF-36, CRQ, or EQ-5D PROs were found to enable any meaningful assessment of their relationships.

Correlations between exercise test outcomes and self-reported breathlessness
----------------------------------------------------------------------------

Associations between the BDI and exercise test outcomes were reported for six studies ([Table 3](#t3-copd-12-2487){ref-type="table"}; [Figure 3](#f3-copd-12-2487){ref-type="fig"}).[@b36-copd-12-2487],[@b44-copd-12-2487],[@b48-copd-12-2487],[@b52-copd-12-2487],[@b55-copd-12-2487],[@b56-copd-12-2487] Four articles noted an association between the 6MWT and BDI score: three publications reported moderate--very strong Pearson's correlations (*r*=0.47--0.86),[@b44-copd-12-2487],[@b48-copd-12-2487],[@b56-copd-12-2487] with another reporting a moderate Spearman's correlation (*ρ*=0.49).[@b55-copd-12-2487] Only one study assessing this relationship found no significant correlation.[@b52-copd-12-2487] Two additional publications reported moderate--strong Pearson's correlations between the BDI and ISWT (−0.46[@b36-copd-12-2487] and 0.76[@b48-copd-12-2487]), with another reporting no significant correlation.[@b55-copd-12-2487] The positive correlations demonstrated in these studies show that PRO scores increase as exercise performance improves, indicating improved health status.

Associations between OCD and exercise test outcomes were reported in seven articles ([Table 3](#t3-copd-12-2487){ref-type="table"}; [Figure 3](#f3-copd-12-2487){ref-type="fig"}).[@b36-copd-12-2487],[@b39-copd-12-2487],[@b40-copd-12-2487],[@b44-copd-12-2487],[@b50-copd-12-2487],[@b51-copd-12-2487],[@b56-copd-12-2487] Of these, three publications reported weak--moderate Pearson's correlations between the 6MWT and the OCD, ranging from 0.34 to 0.52,[@b40-copd-12-2487],[@b44-copd-12-2487],[@b56-copd-12-2487] with a further study finding a strong Spearman's correlation (*ρ*=0.66).[@b50-copd-12-2487] Only one study found no significant correlation between the 6MWT and the OCD.[@b39-copd-12-2487] Single articles noted weak--moderate correlations for the 12MWT (*r*=0.50)[@b51-copd-12-2487] and the ISWT (*r*=0.33),[@b36-copd-12-2487] and a further paper reported strong Spearman's correlations of 0.61 and 0.74 for the ICET, when peak VO~2~ and W~max~ were used for the main outcome measure, respectively.[@b50-copd-12-2487] The same study also found moderate (*ρ*=0.59) correlations between the OCD and the ECET. Of six studies[@b41-copd-12-2487],[@b47-copd-12-2487],[@b52-copd-12-2487],[@b53-copd-12-2487],[@b56-copd-12-2487],[@b61-copd-12-2487] reporting Pearson's correlations between the 6MWT and the MRC/mMRC scale, five[@b41-copd-12-2487],[@b47-copd-12-2487],[@b53-copd-12-2487],[@b56-copd-12-2487],[@b61-copd-12-2487] reported *r*-values ranging from −0.51 to −0.7. However, one of these studies reporting Pearson's correlations between the 6MWT and the MRC/mMRC scale described *r*^2^ rather than *r*. For the basis of this analysis, this study was included under the assumption that a Pearson's correlation was used and *r[@b2-copd-12-2487]* was a typographical error.[@b61-copd-12-2487] One study[@b52-copd-12-2487] reported no significant correlation ([Table 3](#t3-copd-12-2487){ref-type="table"}; [Figure 3](#f3-copd-12-2487){ref-type="fig"}), and another two studies reported a significant Spearman's correlation between MRC/mMRC and the 6MWT (−0.51[@b39-copd-12-2487] and −0.39[@b38-copd-12-2487]). The negative correlations demonstrated in these studies show that PRO scores decrease as exercise performance improves, indicating improved health status.

Discussion
==========

This systematic review has shown that there are limited studies available reporting on the correlations between exercise test outcomes and PROs. Of these, the body of evidence describing a relationship between these outcome measures is even smaller. The most commonly reported association was between SGRQ~total~ outcomes and distance covered in the 6MWT. Though typically significant, these correlations were generally weak--moderate. The available evidence also showed correlations between the SGRQ~total~ and SGRQ~activity~ and the ISWT, ICET (W~max~), ECET, and TT, which tended to be moderate--strong. No studies were found that assessed associations between exercise test and SGRQ outcomes (including all subscales) for 12MWT and ESWT. However, all of these correlations must be considered in the context of substantial heterogeneity in study design, disease severity, and sample size.

The majority of studies investigating associations between exercise test outcomes and self-reported breathlessness scores, such as the BDI, OCD, and mMRC, have used the 6MWT. The PROs of these tended to exhibit at least moderate correlations with exercise test outcomes. In particular, the BDI was generally reported to have a moderate--very strong Pearson's correlation with the 6MWT in three of four studies, with a further study reporting a moderate Spearman's correlation for this relationship.

Among included studies, there was a wide range of study designs and patient cohorts. As high-quality evidence is limited in this field, observational studies were combined with the results of randomized controlled trials, with the risk of affording similar weight to their interpretation. It is thus possible that significant associations could be underrecognized, owing to a type II statistical reporting error, a factor that must be considered when designing or interpreting studies to assess these exercise tests. Many of these studies reported nonsignificant correlations. Given the number of studies with small patient numbers that did report significant correlations, sample size is unlikely to be a factor in the nonsignificant correlations demonstrated by some studies. However, substantial heterogeneity was observed among some of the patient populations in terms of baseline demographics.

There are also inconsistencies in the way in which results were reported, with some study publications reporting incongruous negative/positive correlations compared with others describing the same relationship. It is unclear whether this reflects differences in the way in which the instruments were used or the way in which the statistical tests were applied between instruments and exercise test outcomes. We have presented such values as reported in the source articles. Additionally, the inclusion criteria and COPD severity are often not clearly stated in the articles included in this review. There is thus a risk that the patients in the studies included were not a broadly homogeneous group. Therefore, we would recommend that future studies clearly state inclusion criteria and the clinical rationale for diagnosis whenever possible.

Although not included in the review, consideration should also be given to the correlations demonstrated in studies that fell outside the selected search criteria. Several studies that were not included here showed significant relationships between exercise and breathlessness or PROs, either demonstrating correlations with new tools or using correlation coefficients other than Pearson's or Spearman's. For example, associations between exercise capacity and the i-BODE index (body-mass index, airflow obstruction, dyspnea, exercise-capacity index \[exercise-capacity measured using ISWT\]),[@b63-copd-12-2487] the Functional Assessment of Chronic Illness Therapy -- fatigue (FACIT-F) instrument,[@b64-copd-12-2487] the London Chest Activity of Daily Living (LCADL) scale,[@b65-copd-12-2487] and the McGill Pain Questionnaire (MPQ)[@b66-copd-12-2487] were identified in patients with COPD. Moreover, correlations between the 6MWT and the COPD assessment test (CAT)[@b67-copd-12-2487] and between the desaturation:distance ratio (DDR) and Borg scale[@b68-copd-12-2487] have been identified. The criteria chosen for this review were based on well-established PROs, rather than those that have been more recently developed. However, many of these more novel tests are increasing in popularity, and as such, further investigation into their correlation with breathlessness or HRQoL PROs will be useful to determine their relevance in predicting prognosis in patients with COPD.

Despite the noted limitations, three further recommendations can be drawn directly from these findings. First, one of our included studies reported correlations between two PRO measures (SGRQ~total~ and OCD) and two common outcome measures for the ICET: peak VO~2~ and W~max~. In both, the PRO was more closely correlated with the ICET W~max~ than the ICET peak VO~2~. This finding complements that of another systematic review conducted by these authors,[@b69-copd-12-2487] which showed that exercise test outcomes tended to be more closely correlated with W~max~ as a measure of lung function than with peak VO~2~. It thus seems prudent to suggest that when investigating ICET, researchers report W~max~ values as a priority.

Second, as a combination of the SF-36 and EQ-5D is the instrument of choice for assessing HRQoL of several health technology-assessment bodies, the lack of studies reporting associations between this outcome measure and exercise tests is of note. Clinical trial designers might usefully consider this in assessing the most appropriate clinical trial end point. Third, the results of this review suggest that exercise tests are not interchangeable, and as such, comparisons of different exercise tests in response to interventions are inappropriate.

In conclusion, these findings indicate that only limited evidence is available to support an association between exercise test outcomes and HRQoL and breathlessness PROs in patients with COPD. The evidence that does exist suggests a very weak--moderate negative correlation between the 6MWT and the SGRQ. Both moderate--strong positive and negative correlations between 6MWT outcomes and breath-lessness were observed. It has not been possible to assess other tests adequately, though the limited data available suggest that the ISWT, ICET, ECET, and TT may be more closely associated with the SGRQ (and HRQoL outcomes) than the 6MWT. Recent guidelines on the diagnosis and treatment of COPD indicate that the assessment of disease severity is improved by using functional criteria, such as exercise capacity.[@b4-copd-12-2487],[@b70-copd-12-2487],[@b71-copd-12-2487] However, the current evidence suggests that no single exercise test accurately reflects HRQoL or breathlessness in patients with COPD. Therefore, despite the paucity of data for some tests, it may be justified to conclude that these tests assess features not measured by these HRQoL outcomes. Consequently, a composite measurement assessing several factors reflective of COPD, such as the BODE index, which evaluates a surrogate of nutritional state (body-mass index), airflow obstruction (FEV~1~), dyspnea (mMRC), and exercise capacity (6MWT), may be a more accurate measure of COPD severity and prognosis.[@b72-copd-12-2487] The BODE index predicts the requirement for hospitalizations among patients with COPD better than either FEV~1~ or classic GOLD staging.[@b73-copd-12-2487] It thus seems reasonable to surmise that individual PROs may have limited prognostic ability in patients with COPD, and should be supported by additional measurements wherever possible.
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![PRISMA-compliant screening and identification process.\
**Abbreviation:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](copd-12-2487Fig1){#f1-copd-12-2487}

![Pearson's correlations in studies reporting significant associations between exercise test outcomes and SGRQ~total~.\
**Notes:** Numbers in parentheses refer to studies reporting significant correlations/total number of studies reporting Pearson's correlations. Negative correlations indicate reduced SGRQ~total~ scores with improvements in exercise test performance. Lower SGRQ scores indicate improved health status.\
**Abbreviations:** 6MWT, 6-minute walk test; 12MWT, 12-minute walk test; ECET, endurance cycle ergometer test; ESWT, endurance shuttle walk test; ICET, incremental cycle ergometer test; ISWT, incremental shuttle walk test; peak VO~2~, peak rate of oxygen consumption; SGRQ~total~, St George's Respiratory Questionnaire total score; TT, treadmill test; W~max~, highest workload achieved.](copd-12-2487Fig2){#f2-copd-12-2487}

![Pearson's correlations in studies reporting significant associations between the 6-minute walk-test outcomes and breathlessness PROs.\
**Notes:** Numbers in parentheses refer to studies reporting significant correlations/total number of studies reporting Pearson's correlations. The two positive correlations shown here indicate higher PRO scores with improvements in exercise test performance. Higher PRO scores indicate improved health status. Negative correlations indicate lower PRO scores with improvements in exercise test performance. Lower PRO scores indicate improved health-related quality of life.\
**Abbreviations:** BDI, Baseline Dyspnea Index; mMRC, modified Medical Research Council (dyspnea scale); PRO, patient-reported outcome; OCD, oxygen-cost diagram.](copd-12-2487Fig3){#f3-copd-12-2487}
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                  Country, N                              Study design/details                                                                                                                                                                                                                                                                                           Study duration/follow-up period                                                                                                                                                                                                                          Inclusion and exclusion                                                                                                                                                                                                                                                                                                                                                                                       Age (years), sex (n), BMI (kg/m^2^)   Disease severity (staging method, score)                                                   Pulmonary function
  ------------------------------------------------------ --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------
  Agrawal et al[@b59-copd-12-2487]                       India, N=129                            Aimed to identify the correlation between HRQoL using SGRQ and functional exercise capacity using 6MWT in patients with COPD                                                                                                                                                                                   Patients screened July 1, 2009--June 30, 2010, and recalled their symptoms over 1 month--1 year                                                                                                                                                          Inclusion: \>40 years old, postbronchodilator FEV~1~/FVC \<70% predicted\                                                                                                                                                                                                                                                                                                                                     Age: mean 60.96±11.5\                 GOLD\                                                                                      FEV~1~, L: 1.19±0.62\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: coexisting lung lesions on chest radiograph, ischemic heart disease on electrocardiography, serum creatinine \>1.4 mg/dL, those with confirmed COPD with any contraindications for 6MWT, as given by the ATS                                                                                                                                                                                       Male: 99 (76.74%)\                    Stage I (mild): 15 (11.6%)\                                                                FEV~1~, % predicted: 53.68±21.1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 19.13±3.55                       Stage II (moderate): 60 (46.5%)\                                                           FEV~1~/FVC: 58.67±9.83
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Stage III (severe): 37 (28.6%)\                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Stage IV (very severe): 17 (13.3%)                                                         

  Bavarsad et al[@b60-copd-12-2487]                      Iran, N=36                              Cross-sectional study to investigate relationships among 6MWT, dyspnea, QoL, and disease severity and to identify the predictors of 6MWT in patients with COPD                                                                                                                                                 Patients assessed during an outpatient pulmonary clinic                                                                                                                                                                                                  Inclusion: mild--very severe COPD according to GOLD criteria, 40--70 years old, presenting stable clinical condition without exacerbations in preceding month\                                                                                                                                                                                                                                                Age: mean 56.8±8.8\                   Mild--very severe COPD as per GOLD                                                         FEV~1~, L: 1.86±0.89\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: comorbid conditions likely to reduce exercise capacity eg, unstable angina and MI during previous month and BMI \>35 kg/m^2^, weaning dose of oral corticosteroids, cognitive deficit and musculoskeletal disorders, increasing FEV~1~ ≥12% following bronchodilator (salbutamol) therapy and consumption of bronchodilator during 6MWT                                                            Male: 33 (91.7%)\                                                                                                                FEV~1~, % predicted: 57.8±24.7\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 24.9±4.7                                                                                                                    FVC, L: 3.19±1.06\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        FVC, % predicted: 80±22.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        FEV~1~/FVC, %: 69.6±16.5

  Belza et al[@b34-copd-12-2487]                         US, N=63                                Cross-sectional, descriptive                                                                                                                                                                                                                                                                                   Assessments conducted over 4 days                                                                                                                                                                                                                        Inclusion: veterans with COPD about to enter PR program who had not been hospitalized within past 2 months for respiratory problems\                                                                                                                                                                                                                                                                          Age: 65.4±8\                          Moderate--severe COPD (based on FEV~1~)                                                    FEV~1~, % predicted: 36±16
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: veterans with severe, unstable cardiovascular disease or rapidly declining clinical course                                                                                                                                                                                                                                                                                                         Male: 60\                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 3\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  

  Benzo and Sciurba[@b35-copd-12-2487]                   US, N=50                                Aimed to report range of VO~2~ associated with each minute walked during shuttle walk test                                                                                                                                                                                                                     Single shuttle walk test performed 30 minutes after bronchodilators during regular scheduled COPD clinic visit                                                                                                                                           Inclusion: stable COPD\                                                                                                                                                                                                                                                                                                                                                                                       Age: 60±12\                           Mild/severe, according to GOLD guidelines                                                  FEV~1~, % predicted: 60.5±23.1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: acute respiratory symptoms, using antibiotics or oral prednisone in preceding 2 weeks, any physical impediment to walking                                                                                                                                                                                                                                                                          Male: 24\                                                                                                                        FVC, % predicted: 77.7±17.9
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 26\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 28±6                                                                                                                        

  Boer et al[@b36-copd-12-2487]                          the Netherlands, N=128 (64 with COPD)   Cross-sectional, to evaluate whether activity-based dyspnea scales can substitute for actual functional capacity testing in patients with COPD                                                                                                                                                                 Patients were enrolled between January 2001 and November 2001                                                                                                                                                                                            Inclusion: smokers with COPD or at risk of COPD\                                                                                                                                                                                                                                                                                                                                                              Age: 51.7±7.7\                        GOLD At risk of COPD: 63\                                                                  FEV~1~, L: 2.74±0.92\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: smoking history \<5 years, history of asthma, acute exacerbation or changes in respiratory treatment regimen in preceding 4 weeks, concomitant comorbidity that may influence functional capacity (ie, cardiovascular, neurologic, or endocrine diseases, and/or locomotive limitations)                                                                                                           Male: 57\                             Stage I (mild): 31\                                                                        FEV~1~, % predicted: 90.8±23.1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 71\                           Stage II (moderate): 22\                                                                   FVC, L: 4.03±1.04\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 25±3.9                           Stage III (severe): 11                                                                     FVC, % predicted: 111.2±17.8

  Brown et al[@b37-copd-12-2487]                         US, N=1,218                             Randomized, double-blind, two-period crossover to compare cardiopulmonary exercise testing and 6MWT in patients with emphysema to determine degree of impairment[@b74-copd-12-2487],[@b75-copd-12-2487]                                                                                                        Assessments conducted within 6-week period during baseline evaluation, before pulmonary rehabilitation and randomization to National Emphysema Treatment Trial                                                                                           Inclusion: with COPD, enrolled in National Emphysema Treatment Trial, with radiographic evidence of emphysema, FEV~1~ ≤45% predicted, TLC ≥100% predicted, RV ≥150% predicted, and PaCO~2~ ≤60 mmHg who had not smoked in prior 4 months and did not have severe comorbid conditions\                                                                                                                         Age: 66.6±6.13\                       With COPD with severe or very severe emphysema who were participating in a trial of LVRS   FEV~1~, L: 0.77±0.24\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 746\                                                                                                                       FEV~1~, % predicted: 26.9±7.12\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 472\                                                                                                                     FVC, L: 2.5±0.78\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 24.7±3.88                                                                                                                   FVC, % predicted: 66.8±15.2

  Callens et al[@b38-copd-12-2487],[@b74-copd-12-2487]   France, N=50                            Two-part study to determine evidence for dynamic hyperinflation after walking with handheld spirometer and to determine functional consequences in patients with COPD                                                                                                                                          ND                                                                                                                                                                                                                                                       Inclusion: consecutive patients with COPD receiving their regular treatment, current or past smokers (history of \>15 pack-years), clinically stable for preceding 8 weeks\                                                                                                                                                                                                                                   Group 1 (n=20)\                       GOLD: group 1, group 2\                                                                    Group 1, group 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: history suggesting asthma, active heart disease, musculoskeletal disorders, peripheral vascular diseases, or other disabling conditions that would interfere with tests                                                                                                                                                                                                                            Median age: 61 (IQR 55--71)\          Stage I (mild): 4, 2\                                                                      FEV~1~, % predicted: 52 (IQR 37--76), 42 (IQR: 30--57)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 12\                             Stage II (moderate): 6, 10\                                                                FEV~1~/FVC, %: 55 (IQR 44--71), 51 (IQR 41--63)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 8\                            Stage III (severe): 7, 11\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Median BMI: 23.6 (22.1--28)\          Stage IV (very severe): 3, 7                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Group 2 (n=30)\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Median age: 60 (IQR 54--68)\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 27\                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 3\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Median BMI: 25.3 (21--26.8)                                                                                                      

  Camargo and Pereira[@b39-copd-12-2487]                 Brazil, N=50                            To determine correlations among various dyspnea scales, spirometric data, and 6MWT in symptomatic patients with COPD                                                                                                                                                                                           Patients enrolled between March 2008 and July 2009                                                                                                                                                                                                       Inclusion: consecutive patients with symptomatic COPD (≥40 years old) treated between March 2008 and July 2009, with documented postbronchodilator FEV~1~ ≤65% of predicted within last 12 months, with smoking history ≥10 pack-years\                                                                                                                                                                       Age: 69±8\                            Not stated                                                                                 FEV~1~, L: 1.3±0.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: dyspnea from any other cause than COPD; those using supplemental oxygen, those unable to perform 6MWT, answer dyspnea questionnaires, or perform pulmonary function tests, presenting with exacerbation in the last 3 months, presenting with radiological abnormalities indicative of other conditions                                                                                            Male: 35\                                                                                                                        FEV~1~, % predicted: 52±12\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 15\                                                                                                                      FVC, L: 2.7±0.7\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 27±5                                                                                                                        FVC, % predicted: 85±14

  Chuang et al[@b40-copd-12-2487]                        US/Taiwan, N=27                         Measured self-assessed daily activities, scored using oxygen-cost diagram, pulmonary function testing, 6MWT, increasing ramp-pattern cardiopulmonary exercise test performed on cycle ergometer to maximum in patients with COPD                                                                               Assessments conducted at study entry and exercise tests completed in a random order                                                                                                                                                                      Inclusion: outpatients with clinically stable COPD receiving regular schedule of administered bronchodilators with or without oral prednisolone (\<10 mg/day), who had peak exercise heart rate ≥85% of maximally predicted, RER ≥1.09 at peak exercise, at least 4 mmol/L decrease from resting baseline in plasma bicarbonate at peak exercise.\                                                            Age: 65±6\                            Moderate--severe COPD, based on most (\~90%) patients with FEV~1~/VC \<65%                 FEV~1~, L: 1.2±0.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: significant arrhythmia or history of malignancy, cardiovascular, or peripheral vascular disease, or locomotion problems                                                                                                                                                                                                                                                                            Male: 27\                                                                                                                        FEV~1~, % predicted: 49±1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 0\                                                                                                                       FVC, L: 2.8±0.5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  

  Cote et al[@b41-copd-12-2487]                          US, N=365                               Prospective study to compare capacity of the peak VO~2~ and 6MWT in predicting mortality in COPD patients and to identify thresholds associated with this outcome                                                                                                                                              Assessments conducted at study entry and after mean follow-up of 67 months                                                                                                                                                                               Inclusion: consecutive COPD patients recruited to BODE protocol between 1994 and 2005, with smoking history \>10 pack-years, FEV~1~/FVC \<0.7, response to bronchodilation 12% or 200 mL, clinically stable for preceding 6 weeks\                                                                                                                                                                            Age: 67±8\                            "Wide range of COPD severity"                                                              FEV~1~, L: 1.2±0.48\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male/female: "mostly men"\                                                                                                       FEV~1~, % predicted: 40±14\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 26.8±5.4                                                                                                                    FVC, L: 2.8±0.79

  de Torres et al[@b42-copd-12-2487]                     Spain, N=146                            FEV~1~-matched case series to explore factors contributing to sex differences in QoL of COPD patients                                                                                                                                                                                                          Patients recruited over 5 years, January 2000--December 2005                                                                                                                                                                                             Inclusion: 73 consecutive female patients with COPD attending a pulmonary clinic from January 2000 to December 2005 plus 73 randomly selected male patients with COPD with a similar degree of airflow obstruction; all patients with smoking history ≥20 pack-years, postbronchodilator FEV~1~/FVC \<0.7, and clinically stable\                                                                             Age: 63±8 (male); 56±11 (female)\     GOLD stages I--IV                                                                          Not stated
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: history of asthma, bronchiectasis, tuberculosis, or other confounding diseases                                                                                                                                                                                                                                                                                                                     Male: 73\                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 73\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 27±4 (male); 25±7 (female)                                                                                                  

  Dowson et al[@b43-copd-12-2487]                        UK, N=29                                Investigated whether density-mask analysis of high-resolution computed tomography or exercise capacity were better surrogates for health status in a well-defined, homogeneous group of patients with a~1~-antitrypsin deficiency                                                                              Recruitment based on date of annual ATD assessment and program for treatment assessment; lung-function testing conducted on same day as clinical assessments and after receiving salbutamol 5 mg or terbutaline 5 mg and ipratropium bromide 500 mg      Inclusion: α~1~-ATD and macroscopic emphysema selected consecutively from α~1~-ATD treatment center\                                                                                                                                                                                                                                                                                                          Median age: 52 (IQR 46--60)\          Moderate--severe airflow obstruction                                                       Median FEV~1~, L: 1.03 (IQR 0.84--1.41)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: asthma, bronchiectasis, liver disease, or other medical problems likely to limit exercise or alter health status                                                                                                                                                                                                                                                                                   Male: 19\                                                                                                                        Median FEV~1~, %predicted: 35\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 10\                                                                                                                      Median FEV~1~/VC, L: 0.31 (IQR 0.25--0.43)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  Median FEV~1~/VC, % predicted: 37

  Eakin et al[@b44-copd-12-2487]                         US, N=143                               To evaluate dimensions underlying dyspnea ratings, lung function, and respiratory muscle pressures                                                                                                                                                                                                             Assessment at baseline, posttreatment with either instruction, and practice in techniques of progressive muscle relaxation, breathing retraining, pacing, self-talk, and panic control or general health education, and at 6 months[@b76-copd-12-2487]   Inclusion: diagnosis of COPD with no concomitant medical illnesses that exacerbated functional limitations\                                                                                                                                                                                                                                                                                                   Age: 67.5±9\                          COPD diagnosis by clinical history and pulmonary function tests                            FEV~1~, L: 1.22±0.57\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 69\                                                                                                                        FEV~1~, % predicted: 53±24\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 74\                                                                                                                      FVC, L: 2.54±0.9\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  FVC, % predicted: 77±21

  Emtner et al[@b45-copd-12-2487]                        Sweden, N=21                            Prospective study to evaluate independent contribution of exercise capacity (walking distance) to rehospitalization in COPD patients hospitalized with acute exacerbations of obstructive lung disease                                                                                                         Assessment at discharge and 4--6 weeks after discharge, when in stable condition                                                                                                                                                                         Inclusion: consecutive patients admitted to hospital with acute exacerbation of COPD; split into two groups for baseline parameters, but not for analyses\                                                                                                                                                                                                                                                    No-hospitalization group (n=12)\      Disease severity not stated                                                                No hospitalization, hospitalization\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Age: 65±10\                                                                                                                      FEV~1~, % predicted: 40±12, 32±17
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 2\                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 10\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 23±4\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Hospitalization group (n=9)\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age: 65±9\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 5\                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 4\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 22±4                                                                                                                        

  Heijdra et al[@b46-copd-12-2487]                       US, N=41                                Observational, prospective study to explore whether differences in QoL between smokers and ex-smokers could be explained by cough and phlegm, differences in pulmonary function tests, or exercise capacity                                                                                                    Patients asked to describe symptoms from previous year                                                                                                                                                                                                   Inclusion: COPD, participating in a cohort longitudinal study of COPD patients, \>55 years old, FEV~1~ \<55% predicted, stable disease on medical treatment, with ability to understand and complete SGRQ\                                                                                                                                                                                                    Age: 66±8\                            COPD defined by ATS guidelines                                                             FEV~1~, L: 0.97±0.3\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: myocardial infarction within 6 months, ventilator dependency, malignancy, congestive heart failure, hepatic cirrhosis, end-stage renal disease, orthopedic conditions precluding 6MWT performance, or history of psychiatric or neurologic illness that interfered with the study                                                                                                                  Male: 19\                                                                                                                        FEV~1~, % predicted: 38±11
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 22\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 26±6                                                                                                                        

  Hillman et al[@b47-copd-12-2487]                       Australia, N=26                         To evaluate influence of body composition and peripheral muscle strength on 6MWT using dual-energy X-ray absorptiometry scanning, spirometry, and dynamometry                                                                                                                                                  ND                                                                                                                                                                                                                                                       Inclusion: ≤85 years old with severe--very severe COPD and minimum smoking history of 20 pack-years recruited from three PR programs\                                                                                                                                                                                                                                                                         Age: 71±8\                            GOLD Stage III (severe): 14\                                                               FEV~1~, L: 0.9±0.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 13\                             Stage IV: 12                                                                               FEV~1~, % predicted: 32±11
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 13\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 25.4±4.6                                                                                                                    

  Hodgev et al[@b48-copd-12-2487]                        Bulgaria, N=20                          To compare cardiovascular and dyspnea responses to 6MWT and ISWT in patients with COPD                                                                                                                                                                                                                         Assessment within 2 days                                                                                                                                                                                                                                 Inclusion: clinically stable COPD patients who had not received systemic steroids at least 2 months before study, but did receive therapy with bronchodilators during the study\                                                                                                                                                                                                                              Age: 55.9±8.7\                        As per guidelines recommended by National Consensus Conference                             FEV~1~, L: 1.35±0.72\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: history of asthma, allergic rhinitis, atrophy, active lung tuberculosis, lung carcinoma, cardiovascular disorders, including myocardial infarction, angina pectoris, pericarditis, valvular diseases (except relative tricuspid insufficiency), arrhythmia, and arterial hypertension requiring drug treatment, disorders of locomotor apparatus, anemias, kidney, liver, or metabolic disorders   Male: 20\                                                                                                                        FEV~1~, % predicted: 42±19
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 0\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 27.8±7.7                                                                                                                    

  Kaplan et al[@b58-copd-12-2487]                        US, N=1,218                             Report to evaluate QoL measures before randomization in National Emphysema Treatment Trial                                                                                                                                                                                                                     Assessment during \>6--10-week rehabilitation program before randomization in National Emphysema Treatment Trial                                                                                                                                         Inclusion: from National Emphysema Treatment Trial with radiographic evidence of bilateral emphysema and severe airflow obstruction and hyperinflation, and had completed a PR program\                                                                                                                                                                                                                       Mean age: 67\                         Severe airflow obstruction                                                                 FEV~1~, L: 0.68±0.22\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: high-risk characteristics for perioperative morbidity and/or mortality, with emphysema thought to be unsuitable for LVRS or with medical conditions or other circumstances making them unable to complete the trial                                                                                                                                                                                Male: 746\                                                                                                                       FVC, L: 2.14±0.72
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 472\                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  

  Mangueira et al[@b49-copd-12-2487]                     Brazil, N=30                            Cross-sectional study to investigate correlations between HRQoL and 6MWT in women with COPD                                                                                                                                                                                                                    Assessed once, on day of first medical visit or at follow-up                                                                                                                                                                                             Inclusion: women with stable COPD monitored via COPD control and treatment program August 4, 2005--October 30, 2006, no exacerbations in preceding 30 days\                                                                                                                                                                                                                                                   Age: 64.5±10.4\                       GOLD Stage I (mild): 14\                                                                   FEV~1~, % predicted: 58.2±26.8\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: recent episode of unstable angina or acute myocardial infarction, presenting with cognitive defect, or having concomitant disease that might impede study performance                                                                                                                                                                                                                              Male: 0\                              Stage II (moderate): 16                                                                    FVC, % predicted: 69.2±26.4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 30\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 23.9±4.4                                                                                                                    

  Oga et al[@b50-copd-12-2487]                           Japan, N=36                             Randomized, double-blind, placebo controlled, crossover study to compare 6MWT, progressive cycle ergometry, and cycle endurance test in COPD patients                                                                                                                                                          Assessments conducted on separate days over 2-week period                                                                                                                                                                                                Inclusion: consecutive male patients with stable COPD from placebo arm of previously reported clinical trial aged \>45 years, smoking history \>20 pack-years, chest radiographs showing hyperinflation, FEV~1~ \<80% predicted, postbronchodilator FEV~1~/FVC \<0.7\                                                                                                                                         Age: 69±7\                            COPD as per ATS guidelines                                                                 FEV~1~, L: 1.07±0.45\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: Patients with exacerbations in preceding 3 months, history of asthma, other diseases likely to affect exercise, or hypoxemia at rest                                                                                                                                                                                                                                                               Male: 36\                                                                                                                        FEV~1~, % predicted: 40.3±16.7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 0\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 20.3±3.2                                                                                                                    

  O'Reilly et al[@b51-copd-12-2487]                      UK, N=10                                Double-blind, placebo-controlled study to evaluate effects of prednisone 30 mg/day on respiratory function                                                                                                                                                                                                     Assessments conducted before and after three 2-week treatment periods                                                                                                                                                                                    Inclusion: males with chronic airway obstruction\                                                                                                                                                                                                                                                                                                                                                             Mean age: 61 (range 52--70)\          Chronic bronchitis (n=8)\                                                                  FEV~1~, L: 0.81±0.21\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 10\                             Radiological features of emphysema (n=2)                                                   FVC, L: 2.56±0.593
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 0\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  

  Pelegrino et al[@b52-copd-12-2487]                     Brazil, N=68                            Cross-sectional study to analyze cardiopulmonary variables in COPD patients with or without depleted lean body mass, before and after 6MWT                                                                                                                                                                     ND                                                                                                                                                                                                                                                       Inclusion: stable COPD and postbronchodilator FEV~1~/FVC \<70% Exclusion: exacerbations within preceding 3 months, signs of water retention, cardiovascular or osteoarticular diseases                                                                                                                                                                                                                        Age: 64.3±9.2\                        COPD stage\                                                                                Not stated
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 49\                             Mild: 15\                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 19\                           Moderate: 23\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 25.3±4.9                         Severe or very severe: 30                                                                  

  Peruzza et al[@b53-copd-12-2487]                       Italy, N=60                             To investigate impact of COPD on QoL and functional status in elderly using anthropometric measurements, lung-function tests, exercise-tolerance evaluation, and multidimensional assessment                                                                                                                   Trial procedures completed during regular checkup visits as outpatients at geriatric day hospital                                                                                                                                                        Inclusion: COPD \>65 years of age\                                                                                                                                                                                                                                                                                                                                                                            Age: 74.5±5.8\                        As per ERS criteria                                                                        FEV~1~, L: 1.1±0.5\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: underweight (BMI \<18.5) or obese (BMI \<30), ischemic heart disease, experienced changes in medication in preceding 30 days, hospital admission in preceding 6 weeks                                                                                                                                                                                                                              Male: 60\                                                                                                                        FEV~1~, % predicted: 48.1±18.3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 0\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 25.1±3.8                                                                                                                    

  Rejeski et al[@b54-copd-12-2487]                       US, N=209                               To assess test--retest reliability of performance tests                                                                                                                                                                                                                                                        Assessments scheduled within 2 weeks                                                                                                                                                                                                                     Inclusion: COPD, 55--80 years old, self-reported disability attributed to breathlessness when performing daily activities, prior or current history of smoking, FEV~1~/FVC ≤70%, FEV~1~ \>20% predicted\                                                                                                                                                                                                      Age: 67.2±6\                          ATS\                                                                                       FEV~1~, L: 1.57±0.58\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 117\                            Stage I (mild): 134\                                                                       FEV~1~, % predicted: 57.1±17
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 92\                           Stage II (moderate): 55\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                       Stage III (severe): 20                                                                     

  Rosa et al[@b55-copd-12-2487]                          Brazil, N=24                            Cross-sectional, descriptive study to evaluate applicability of incremental (shuttle) walk test compared with encouraged 6MWT in COPD patients                                                                                                                                                                 Assessments carried out over 1 day                                                                                                                                                                                                                       Inclusion: consecutive COPD patients from pulmonary rehabilitation center with PaO~2~ 55 mmHg or SpO~2~ 92% (at rest and on room air), at least 6 weeks of clinical stability and satisfactory ability to walk unaided\                                                                                                                                                                                       Age: 67.8±7.5\                        GOLD\                                                                                      FEV~1~, % predicted: 48.6±21\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: SpO~2~ of 80% during exercise, with other pulmonary diseases, heart diseases, cardiac insufficiency, or other comorbidities considered uncontrolled or significant, and those presenting with formal contraindications to performing exercise tests                                                                                                                                                Male: 17\                             Stage I (mild): 2\                                                                         FVC, % predicted: 80.9±21
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 7\                            Stage II (moderate): 7\                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 24.2±4.2                         Stage III (severe): 12\                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Stage IV: 3                                                                                

  Sun et al[@b61-copd-12-2487]                           Taiwan, N=200                           Prospective cross-sectional study to investigate association between asymptomatic PAD and walking endurance, measured by the 6MWT in patients with COPD                                                                                                                                                        Patients over 4 years of age enrolled                                                                                                                                                                                                                    Inclusion: 46--89 years of age with postbronchodilator FEV~1~/FVC \<0.7, without PAD or with asymptomatic PAD (PAD^−^/PAD^+^)\                                                                                                                                                                                                                                                                                PAD^−^\                               COPD as per GOLD; severity not stated                                                      PAD^−^\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: history of bronchial asthma and other structural lung diseases, not current or former smokers with at least a 10-pack-year history                                                                                                                                                                                                                                                                 Age: 70.9±9\                                                                                                                     FEV~1~: 1.28±0.5\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 184 (98.9%)\                                                                                                               FEV~1~, % predicted: 56.5±18\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 22.8±3.5\                                                                                                                   FEV~1~/FVC: 54.8±8\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PAD^+^\                                                                                                                          PAD^+^\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Age: mean 71.9±9\                                                                                                                FEV~1~: 1.2±0.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Male: 17 (100%)\                                                                                                                 FEV~1~, % predicted: 55.9±19\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: 24.1±3.5                                                                                                                    FEV~1~/FVC: 52.9±9

  Wegner et al[@b56-copd-12-2487]                        Germany, N=62                           To examine relationship between exercise capacity, as assessed by standardized 6MWT, lung-function parameters, and clinical ratings of dyspnea                                                                                                                                                                 Patients assessed over 5 days                                                                                                                                                                                                                            Inclusion: stable COPD with history of progressing dyspnea on exertion, no history of atopy, FEV~1~ \<65% predicted, no other major illnesses that might affect exercise performance\                                                                                                                                                                                                                         Age: 66±9\                            Severe COPD, as per ATS guidelines                                                         FEV~1~, L: 1.1±0.4\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: not stated                                                                                                                                                                                                                                                                                                                                                                                         Male: 51\                                                                                                                        FEV~1~, % predicted: 39±13\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Female: 11\                                                                                                                      VC, L: 3.4±0.9\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  VC, % predicted: 90±16

  Wijkstra et al[@b57-copd-12-2487]                      the Netherlands, N=40                   To investigate relative contribution of lung function, maximal inspiratory pressure, dyspnea, and QoL to performance in walking-distance and bicycle ergometer tests in patients with COPD using measurements of lung function, maximal inspiratory pressure, QoL, dyspnea assessment, and exercise capacity   Patients assessed over 2 days after admittance to hospital in stable condition                                                                                                                                                                           Inclusion: known COPD with postbronchodilator FEV~1~ \<60% predicted and FEV~1~/IVC \<50%, clinically stable\                                                                                                                                                                                                                                                                                                 Age: 62.4±5\                          Severe airway obstruction, based on pulmonary function indices                             FEV~1~, L: 1.2±0.3\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Exclusion: evidence of ischemic heart disease, intermittent claudication, musculoskeletal disorders, or other disabling diseases that might restrict PR program                                                                                                                                                                                                                                               Male/female: not stated\                                                                                                         FEV~1~, % predicted: 44.3±10.6\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMI: not stated                                                                                                                  IVC, L: 3.6±0.9\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        IVC, % predicted: 91.3±17.2
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Values presented are mean ± standard deviation unless otherwise stated.

**Abbreviations:** ATD, antitrypsin deficiency; ATS, American Thoracic Society; BMI, body-mass index; BODE, BMI, airflow obstruction, dyspnea and exercise-capacity index; ERS, European Respiratory Society; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-related quality of life; ISWT, incremental shuttle walk tests; IQR, interquartile range; IVC, inspiratory slow vital capacity; LVRS, lung volume-reduction surgery; 6MWT, six-minute walk test; MI, myocardial infarction; ND, not described; QoL, quality of life; PAD, peripheral arterial disease; PaO~2~, partial pressure of arterial oxygen; PR, pulmonary rehabilitation; RER, respiratory exchange ratio; RV, residual volume; SGRQ, St George's Respiratory Questionnaire; SpO~2~, arterial oxygen saturation; TLC, total lung capacity; VC, vital capacity.

###### 

Correlations between exercise test outcomes and selected quality-of-life PRO measures

                                                            6MWT                                                                    12MWT    ISWT   ESWT   ICET (VO~2~)               ICET (W~max~)   ECET (t)   TT (VO~2~)                                                                                                                                  
  --------------------------------------------------------- ----------------------------------------------------------------------- -------- ------ ------ -------------------------- --------------- ---------- ------------ -------------------------- ----- -------------------------- ------- -------------------------- ---- -------------------------- ----
  **SGRQ~total~**                                                                                                                                                                                                                                                                                                                                            
  *r*                                                       −0.26[@b37-copd-12-2487]                                                1, 218                 −0.55[@b45-copd-12-2487]   21                                      −0.29[@b41-copd-12-2487]   365   −0.23[@b37-copd-12-2487]   1,218                                                              
                                                            −0.26[@b59-copd-12-2487]                                                129                                                                                                                                                                                                                      
                                                            −0.37[@b41-copd-12-2487]                                                365                                                                                                                                                                                                                      
                                                            −0.37[@b49-copd-12-2487]                                                30                                                                                                                                                                                                                       
                                                            −0.39[@b53-copd-12-2487]                                                60                                                                                                                                                                                                                       
                                                            −0.39[@b60-copd-12-2487]                                                36                                                                                                                                                                                                                       
  *ρ*                                                       −0.27[@b42-copd-12-2487],[b](#tfn4-copd-12-2487){ref-type="table-fn"}   146                    −0.55[@b43-copd-12-2487]   29                                      −0.36[@b50-copd-12-2487]   36    −0.49[@b50-copd-12-2487]   36      −0.54[@b50-copd-12-2487]   36   −0.58[@b43-copd-12-2487]   29
                                                            −0.56[@b50-copd-12-2487]                                                36                                                                                                                                                                                                                       
                                                            NS[@b55-copd-12-2487]                                                   24                     NS[@b55-copd-12-2487]      24                                                                                                                                                                     
  Unspecified[a](#tfn3-copd-12-2487){ref-type="table-fn"}   NS[@b38-copd-12-2487],[@b46-copd-12-2487]                               41                                                                                                                                                                                                                       
                                                            NS[@b52-copd-12-2487]                                                   68                                                                                                                                                                                                                       
  **SGRQ~activity~**                                                                                                                                                                                                                                                                                                                                         
  *r*                                                       −0.35[@b37-copd-12-2487],[@b59-copd-12-2487]                            1, 218                 −0.67[@b45-copd-12-2487]   21                                                                       −0.31[@b37-copd-12-2487]   1,218                                                              
                                                            −0.36[@b53-copd-12-2487]                                                60                                                                                                                                                                                                                       
                                                            −0.44[@b60-copd-12-2487]                                                36                                                                                                                                                                                                                       
                                                            NS[@b59-copd-12-2487]                                                   129                                                                                                                                                                                                                      
  *ρ*                                                       −0.68[@b50-copd-12-2487]                                                36                     −0.62[@b43-copd-12-2487]   29                                      −0.51[@b50-copd-12-2487]   36    −0.62[@b50-copd-12-2487]   36      −0.62[@b50-copd-12-2487]   36   −0.58[@b43-copd-12-2487]   29
                                                            NS[@b55-copd-12-2487]                                                   24                     NS[@b55-copd-12-2487]      24                                                                                                                                                                     
  Unspecified[a](#tfn3-copd-12-2487){ref-type="table-fn"}   −0.37[@b46-copd-12-2487]                                                41                                                                                                                                                                                                                       
  **SGRQ~impact~**                                                                                                                                                                                                                                                                                                                                           
  *r*                                                       −0.22[@b37-copd-12-2487]                                                1,218                  −0.53[@b45-copd-12-2487]   21                                                                       −0.2[@b37-copd-12-2487]    1,218                                                              
                                                            −0.28[@b59-copd-12-2487]                                                129                                                                                                                                                                                                                      
                                                            −0.37[@b53-copd-12-2487]                                                60                                                                                                                                                                                                                       
                                                            −0.4[@b60-copd-12-2487]                                                 36                                                                                                                                                                                                                       
  *ρ*                                                       −0.5[@b55-copd-12-2487]                                                 24                     −0.48[@b43-copd-12-2487]   29                                                                                                          −0.5[@b50-copd-12-2487]    36   −0.54[@b43-copd-12-2487]   29
                                                            NS[@b50-copd-12-2487]                                                   36                     NS[@b55-copd-12-2487]      24                                      NS[@b50-copd-12-2487]      36    NS[@b50-copd-12-2487]      36                                                                 
  Unspecified[a](#tfn3-copd-12-2487){ref-type="table-fn"}   NS[@b46-copd-12-2487]                                                   41                                                                                                                                                                                                                       
  **SGRQ~symptom~**                                                                                                                                                                                                                                                                                                                                          
  *r*                                                       −0.03[@b37-copd-12-2487]                                                1,218                                                                                                                      −0.03[@b37-copd-12-2487]   1,218                                                              
                                                            −0.35[@b59-copd-12-2487]                                                129                                                                                                                                                                                                                      
                                                            NS[@b53-copd-12-2487]                                                   60                     NS[@b45-copd-12-2487]      21                                                                                                                                                                     
                                                            NS[@b60-copd-12-2487]                                                   36                                                                                                                                                                                                                       
  *ρ*                                                                                                                                                      −0.34[@b43-copd-12-2487]   29                                                                                                                                          −0.44[@b43-copd-12-2487]   29
                                                            NS[@b50-copd-12-2487]                                                   36                     NS[@b55-copd-12-2487]      24                                      NS[@b50-copd-12-2487]      36    NS[@b50-copd-12-2487]      36      NS[@b50-copd-12-2487]      36                              
                                                            NS[@b55-copd-12-2487]                                                   24                                                                                                                                                                                                                       
  Unspecified[a](#tfn3-copd-12-2487){ref-type="table-fn"}   NS[@b46-copd-12-2487]                                                   41                                                                                                                                                                                                                       
  **SF-36 physical**                                                                                                                                                                                                                                                                                                                                         
  *r*                                                       0.67[@b34-copd-12-2487]                                                 63                                                                                                                         0.18[@b37-copd-12-2487]    1,218                                   0.59[@b43-copd-12-2487]    29
                                                            0.19[@b37-copd-12-2487]                                                 1,218                                                                                                                                                                                                                    
  *ρ*                                                                                                                                                      0.53[@b43-copd-12-2487]    29                                                                                                                                                                     
  **SF-36 mental**                                                                                                                                                                                                                                                                                                                                           
  *r*                                                       0.17[@b58-copd-12-2487]                                                 1,218                                                                                                                                                                                                                    
                                                            NS[@b34-copd-12-2487]                                                   63                                                                                                                                                                                                                       
  *ρ*                                                                                                                                                      0.34[@b43-copd-12-2487]    29                                                                                                                                          0.53[@b43-copd-12-2487]    29
  **CRQ~total~**                                                                                                                                                                                                                                                                                                                                             
  *r*                                                       0.41[@b56-copd-12-2487]                                                 62                                                                                                                                                                                                                       
                                                            0.28[@b34-copd-12-2487]                                                 63                                                                                                                                                                                                                       
  **CRQ~emotional~**                                                                                                                                                                                                                                                                                                                                         
  *r*                                                       NS[@b57-copd-12-2487]                                                   40                                                                                                                         NS[@b57-copd-12-2487]      40                                                                 
                                                            NS[@b54-copd-12-2487]                                                   209                                                                                                                                                                                                                      
  **CRQ~mastery~**                                                                                                                                                                                                                                                                                                                                           
  *r*                                                       0.25[@b54-copd-12-2487]                                                 209                                                                                                                                                                                                                      
                                                            NS[@b57-copd-12-2487]                                                   40                                                                                                                         NS[@b57-copd-12-2487]      40                                                                 
  **CRQ~fatigue~**                                                                                                                                                                                                                                                                                                                                           
  *r*                                                       0.25[@b54-copd-12-2487]                                                 209                                                                                                                                                                                                                      
                                                            NS[@b57-copd-12-2487]                                                   40                                                                                                                         NS[@b57-copd-12-2487]      40                                                                 

**Notes:**

Not stipulated whether *r* or *ρ*;

incorrectly reported as 0.267 in the citation (JP de Torres confirmed via email that −0.267 was the correct correlation coefficient, which has been reported to two decimal places here). Shaded areas indicate that no data were found for the relevant association.

**Abbreviations:** 6MWT, 6-minute walk test; 12MWT, 12-minute walk test; Corr, correlation; CRQ, Chronic Respiratory Disease Questionnaire; ECET, endurance cycle ergometer test; ESWT, endurance shuttle walk test; ICET, incremental cycle ergometer test; ISWT, incremental shuttle walk test; NS, no significance (reported); VO~2~, oxygen consumption; PRO, patient-reported outcome; SF-36, 36-item Short-Form Health Survey; SGRQ, St George's Respiratory Questionnaire; t, time; TT, treadmill test; W~max~, highest workload achieved.

###### 

Correlations between exercise test outcomes and selected patient-reported breathlessness measures

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 6MWT                                                                                                                     12MWT   ISWT                       ESWT   ICET (VO~2~)                                     ICET (W~max~)   ECET (t)   TT (VO~2~)                                                                                                     
  -------------- ------------------------------------------------------------------------------------------------------------------------ ------- -------------------------- ------ ------------------------------------------------ --------------- ---------- ------------ -------------------------- ----- ------------------------- ---- ------------------------- ---- -- --
  **BDI**                                                                                                                                                                                                                                                                                                                                                                      

  *r*            (0.47, 0.65)[@b44-copd-12-2487]                                                                                          143                                       −0.46[@b36-copd-12-2487]                         64                                                                                                                                        

                 0.86[@b48-copd-12-2487]                                                                                                  20                                        0.76[@b48-copd-12-2487]                          20                                                                                                                                        

                 0.54[@b56-copd-12-2487]                                                                                                  62                                                                                                                                                                                                                                   

                 NS[@b52-copd-12-2487]                                                                                                    68                                                                                                                                                                                                                                   

  *ρ*            0.49[@b55-copd-12-2487]                                                                                                  24                                                                                                                                                                                                                                   

                                                                                                                                                                                    NS[@b55-copd-12-2487]                            24                                                                                                                                        

  **OCD**                                                                                                                                                                                                                                                                                                                                                                      

  *r*            0.4[@b40-copd-12-2487]\                                                                                                  27\     0.496[@b51-copd-12-2487]   10     0.33[@b36-copd-12-2487]                          64                                                                                                                                        
                 (0.49, 0.34)[@b44-copd-12-2487]                                                                                          143                                                                                                                                                                                                                                  

                 0.52[@b56-copd-12-2487]                                                                                                  62                                                                                                                                                                                                                                   

  *ρ*            0.66[@b50-copd-12-2487]                                                                                                  36                                                                                                                                 0.61[@b50-copd-12-2487]    36    0.74[@b50-copd-12-2487]   36   0.59[@b50-copd-12-2487]   36      

                 NS[@b39-copd-12-2487]                                                                                                    50                                                                                                                                                                                                                                   

  **MRC/mMRC**                                                                                                                                                                                                                                                                                                                                                                 

  *r*            −0.667[@b61-copd-12-2487]                                                                                                200                                       Correlated (*r* not stated)[@b35-copd-12-2487]   50                                      −0.38[@b41-copd-12-2487]   365   39                        50                                     

                 −0.51[@b53-copd-12-2487]                                                                                                 60                                                                                                                                                                                                                                   

                 −0.52[@b41-copd-12-2487]                                                                                                 365                                                                                                                                                                                                                                  

                 −0.63[@b56-copd-12-2487] (reported as negative in [Table 2](#t2-copd-12-2487){ref-type="table"}, but positive in text)   62                                                                                                                                                                                                                                   

                 −0.7[@b47-copd-12-2487]                                                                                                  26                                                                                                                                                                                                                                   

                 NS[@b52-copd-12-2487]                                                                                                    68                                                                                                                                                                                                                                   

  *ρ*            −0.51[@b39-copd-12-2487]                                                                                                 50                                                                                                                                                                                                                                   

                 −0.39[@b38-copd-12-2487]                                                                                                 50                                                                                                                                                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Parenthesis enclose results of different subgroups within the same study; shaded areas indicate that no data were found for the relevant association.

**Abbreviations:** 6MWT, 6-minute walk test; 12MWT, 12-minute walk test; BDI, Baseline Dyspnea Index; Corr, correlation; ECET, endurance cycle ergometer test; ESWT, endurance shuttle walk test; ICET, incremental cycle ergometer test; ISWT, incremental shuttle walk test; mMRC, modified Medical Research Council (dyspnea scale); NS, no significance (reported); OCD, oxygen-cost diagram; VO~2~, oxygen consumption; t, test; TT, treadmill test; W~max~, highest workload achieved.
